SCHEMBL3576764

SCHEMBL3576764

Cc1nn(-c2ccc(Sc3cccc(C4(C#N)CCOCC4)c3)cc2)c(=O)n1CCN1CCOCC1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 4/20 0.41
CTSK P43235 2/20 0.40
PIK3CD O00329 1/20 0.35
GAA P10253 1/20 0.34
AVPR1B P47901 2/20 0.34
PDE1A P54750 1/20 0.34
PDE1B Q01064 1/20 0.34
PDE1C Q14123 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
CASP1 P29466 1/20 0.34
CASP7 P55210 1/20 0.34
HSD17B10 Q99714 1/20 0.34
MAP2K1 Q02750 2/20 0.33
MAPK13 O15264 1/20 0.33
SRC P12931 1/20 0.33
MAP3K8 P41279 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3567787 0.92 ALOX5 (0.42) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3570551 0.91 ALOX5 (0.44) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3574601 0.91 ALOX5 (0.42) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3579227 0.90 ALOX5 (0.41) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3568405 0.90 ALOX5 (0.43) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3575020 0.89 ALOX5 (0.43) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3579556 0.87 ALOX5 (0.42) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3568598 0.87 ALOX5 (0.42) ALOX5PIK3CDPDE1APDE1BPDE1C
SCHEMBL3570959 0.87 ALOX5 (0.47) ALOX5CTSKPIK3CDPDE1APDE1B
SCHEMBL3574960 0.87 ALOX5 (0.41) ALOX5PIK3CDPDE1APDE1BPDE1C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7674811-B2 5-lipoxygenase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2010-03-09 US claimed
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-01-24 US claimed
EP-1834953-A1 Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors Ranbaxy Laboratories Limited (IN) 2007-09-19 EP claimed
US-7674811-B2 5-lipoxygenase inhibitors RANBAXY LABORATORIES LIMITED (IN) 2010-03-09 US disclosed
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS RANBAXY LABORATORIES LIMITED (IN) 2008-01-24 US disclosed
EP-1834953-A1 Tetrahydropyrane derivatives as 5-lipoxygenase inhibitors Ranbaxy Laboratories Limited (IN) 2007-09-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021080-A1 5-LIPOXYGENASE INHIBITORS ALOX5, ALOX15B, ALOX15 ALOX5 1/4885CTSK 1763/4885PIK3CD 2405/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.